cdx-1135
Recombinant proteinexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT01791686)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Complement receptor type 1INHIBITOR
CR1 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS2RF4H67MOG ↗
- ChEMBLCHEMBL4297720 ↗
Also known as
- cdx-1135
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01791686 | Phase 1 | Jan 1, 2013 | Celldex Therapeutics, University of Iowa |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celldex Therapeutics | For profit | 1 | 1 | 1 | 2013 |
| University of Iowa | Academic/Hospital | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1